The primary reason for this is that our previous study [24], which investigated the immune response in PDAC at longer time points after treatment (12-day assessment for CD8+ and CD4+ cells), showed limited beneficial effects on the ultrasound-treated PDAC tumour growth and immune response at that late stage. This evidence concerns the gene CD8A and neoplasm.